Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer
November 28 2018 - 7:30AM
WP1732 shown to accumulate beneficially
in pancreas
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the
"Company"), a clinical stage pharmaceutical company focused on the
development of oncology drug candidates, all of which are based on
license agreements with The University of Texas System on behalf of
the M.D. Anderson Cancer Center, today announced that data from an
independent test in animal models confirmed, as previously
believed, that its immuno-stimulating STAT3 inhibitor achieves
disproportionately high accumulation in the pancreas.
“Our own sponsored research suggested that
WP1732 might be an ideal candidate for treating pancreatic cancer,”
commented Dr. Donald Picker, Moleculin’s Chief Science
Officer. “Now, we have independent testing with radiolabeled
drug confirming this in animal models. The propensity for
such enhanced pancreatic distribution could be highly beneficial
for a new pancreatic cancer drug.”
Walter Klemp, Moleculin’s Chairman and CEO
added, “Published research shows that the growth and survival of
pancreatic cancer requires activated STAT3 (p-STAT3) and our own
research suggests that WP1732 may be one of the most effective
inhibitors of p-STAT3 that has demonstrated activity in in vivo
models. Confirming the disproportionately high accumumulation
of WP1732 in the pancreas puts us one step closer to introducing an
entirely new approach to treating pancreatic cancer. This is
very encouraging and confirms the direction that Moleculin has
taken with WP1732. We are heavily engaged in preparing the data
necessary for an Investigational New Drug (IND) application with
the FDA which we are targeted to file in 2019.”
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company focused on the development of oncology drug
candidates, all of which are based on discoveries made at M.D.
Anderson Cancer Center. The Company’s clinical stage drugs are
Annamycin, an anthracycline designed to avoid multidrug resistance
mechanisms with little to no cardiotoxicity being studied for the
treatment of relapsed or refractory acute myeloid leukemia, more
commonly referred to as AML, and WP1066, an immuno-stimulating
STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.
Moleculin Biotech is also engaged in preclinical development of
additional drug candidates, including additional STAT3 inhibitors
and compounds targeting the metabolism of tumors.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, the ability of
WP1732 to receive IND status and to show safety and efficacy in
patients. Although Moleculin Biotech believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Moleculin Biotech has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission (“SEC”) and updated
from time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
ContactsJoe Dorame, Robert Blum or Joe
DiazLytham Partners, LLC602-889-9700mbrx@lythampartners.com
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Apr 2023 to Apr 2024